Additionally, in a study published in 2016, it seemed that mutations in TP53 in patients with TNBC were associated with higher levels of TILs in comparison to TP53 mutations in other cancer types, or the same mutation in other subtypes of breast cancer; however, the authors failed to demonstrate any association between TP53 status and pCR in this group of patients. This evidence concerns the gene TP53 and cancer.